A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma.
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2016
At a glance
- Drugs TPI 287 (Primary) ; Temozolomide
- Indications Medulloblastoma; Neuroblastoma
- Focus Adverse reactions
- 05 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Nov 2014 Planned End Date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 02 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.